ArticleInternational journal of nanomedicine2025
Daidzein-Decorated Gold Nanoparticles as a Novel Antimicrobial Strategy Against Carbapenem-Resistant Enterobacteriaceae.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Research Progress on the Anti-Inflammatory and Antioxidant Effects of Daidzein: Its Mechanisms of Action in Related Diseases, and Related Nanoformulations to Enhance Its Bioavailability.Antioxidants (Basel, Switzerland) · 2026Review
- Pre-Target Interception Defines Carbapenem Failure in Carbapenem-Resistant Enterobacterales: A Mechanistic Framework for Spatiotemporal Drug Reprogramming.Pharmaceutics · 2026Review
- Isolation, Screening, and Characterization of Gordonia paraffinivorans DGM-81 Exhibiting Antimicrobial Activity Against Methicillin-Resistant Staphylococcus aureus (MRSA).Current microbiology · 2026Article
- Dual action of herbal compounds inFrontiers in immunology · 2026Review
- Fluconazole-Decorated Gold Nanoparticles as a Novel Therapeutic Strategy Against Carbapenem-ResistantInfection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bacterial resistance to carbapenems is on the rise, and the failure of common antimicrobials poses a serious challenge in treating infections caused by drug-resistant strains. In this scenario, nanomaterials have received widespread attention in medicine. Methods: In this study, the activity of daidzein-decorated gold nanoparticles (Daidzein_Au NPs) against carbapenem-resistant Enterobacteriaceae (CRE) strains was validated via in vivo and in vitro experiments, such as the microdilution broth method, growth curves, time-killing assays, and an abdominal infection model in mice. The potential mechanisms involved were examined using fluorescence quantification of N-phenyl-1-naphthylamine, propidium iodide, and reactive oxygen species (ROS) levels and transcriptomic analysis. Results: Face-centered cubic Daidzein_Au NPs with an average size of 25.78 nm and a negative surface charge were successfully synthesized. The minimum inhibitory concentration (MIC) of Daidzein_Au NPs against the tested CRE strains was 8-16 μg/mL, and they exerted a good antimicrobial effect during the dynamic killing process. In vivo experiments showed that Daidzein_Au NPs can significantly enhance the survival rate (100%) and reduce the colony load of ascites in mice ( Conclusion: Daidzein_Au NPs exhibit excellent antibacterial activity and are expected to become a promising solution to the threats posed by CRE strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.